{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:26:34Z","timestamp":1648599994609},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.diagmicrobio.2007.08.005","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T14:55:16Z","timestamp":1196780116000},"page":"155-161","source":"Crossref","is-referenced-by-count":3,"title":["In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant"],"prefix":"10.1016","volume":"60","author":[{"given":"Jeremy","family":"Schafer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie B.","family":"Hovde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Simonson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Rotschafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib1","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.47.8.2606-2614.2003","article-title":"Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model","volume":"47","author":"Allen","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0732-8893(00)00185-1","article-title":"The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae","volume":"38","author":"Ambrose","year":"2000","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib3","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1128\/AAC.44.11.3049-3054.2000","article-title":"Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance","volume":"44","author":"Bast","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-8579(01)00475-7","article-title":"Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998\u20131999) including an in vitro evaluation of BMS284756","volume":"19","author":"Bell","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.diagmicrobio.2004.08.017","article-title":"Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States","volume":"51","author":"Bhavnani","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1469-0691.2003.00482.x","article-title":"Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae","volume":"9","author":"Brenwald","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2007.08.005_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jac\/45.suppl_3.95","article-title":"Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae","volume":"45","author":"Broskey","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib8","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/AAC.46.1.119-124.2002","article-title":"Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000","volume":"46","author":"Davies","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1574-6968.2002.tb11478.x","article-title":"Screening of large numbers of Streptococcus pneumoniae isolates for mutations associated with fluoroquinolone resistance using an oligonucleotide probe assay","volume":"217","author":"Davies","year":"2002","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jac\/dkg309","article-title":"Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998\u20132000)","volume":"52","author":"Davies","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1128\/AAC.48.4.1215-1221.2004","article-title":"Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae","volume":"48","author":"Florea","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1086\/344768","article-title":"Widespread use of fluoroquinolones versus emerging resistance in pneumococci","volume":"35","author":"Goldstein","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0732-8893(03)00087-7","article-title":"Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program","volume":"46","author":"Gordon","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2007.08.005_bib15","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/320181","article-title":"Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Hoban","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0732-8893(02)00453-4","article-title":"Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae","volume":"44","author":"Ibrahim","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib17","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.40.12.2760","article-title":"High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA","volume":"40","author":"Janoir","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.44.2.462-466.2000","article-title":"Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997\u20131998 respiratory season","volume":"44","author":"Jones","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib18","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1128\/JCM.38.11.4298-4299.2000","article-title":"Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997\u20131999)","volume":"38","author":"Jones","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.diagmicrobio.2004.12.009","article-title":"Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib21","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1128\/AAC.47.6.1790-1797.2003","article-title":"Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000\u20132001 and 2001\u20132002 TRUST studies in the United States","volume":"47","author":"Karlowsky","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/374052","article-title":"Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998\u20132002)","volume":"36","author":"Karlowsky","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3201\/eid0907.020589","article-title":"Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance","volume":"9","author":"Lim","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib24","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1128\/AAC.47.8.2692-2695.2003","article-title":"Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including stains with altered topoisomerases","volume":"47","author":"Morosini","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib25","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/AAC.40.10.2252","article-title":"ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype","volume":"40","author":"Munoz","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jac\/45.5.583","article-title":"Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones","volume":"45","author":"Pestova","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/AAC.46.3.808-812.2002","article-title":"Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae","volume":"46","author":"Piddock","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2007.08.005_bib28","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1086\/324525","article-title":"Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999\u20132000","volume":"34","author":"Thornsberry","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/323086","article-title":"Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy","volume":"184","author":"Urban","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0378-4347(98)00006-1","article-title":"Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography","volume":"709","author":"Wright","year":"1998","journal-title":"J. Chromatogr. B. Biomed. Sci. Appl."},{"key":"10.1016\/j.diagmicrobio.2007.08.005_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jac\/dkg152","article-title":"AUC(0-t)\/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model","volume":"51","author":"Zelenitsky","year":"2003","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T03:58:55Z","timestamp":1588132735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889307003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0732889307003550"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.08.005","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}